

Broad/Harvard GDAC Analysis Pipeline

Nils Gehlenborg | Harvard Medical School & Broad Institute



Broad/Harvard GDAC Analysis Pipeline

Nils Gehlenborg | Harvard Medical School & Broad Institute

With help from

Michael S Noble

Douglas Voet

Lihua Zou

Gordon Saksena

Pei Lin

Hailei Zhang

John Zhang

Richard Park

Sachet Shukla

Spring Liu

Terrence Wu

Peter J Park

Gad Getz


Lynda Chin


The Cancer Genome Atlas Steering Committee Meeting | April 27-29, 2011



Algorithms

- miR: clustering, correlations
- mRNA: clustering, correlation
- Methylation: correlations
- Clinical: correlations
- **CNA:** GISTIC2, correlations
- Mutations: MutSig, MutationAssessor, correlations
- **Pathways:** Paradigm, EnrichedGenes






Scalable solution for standard analyses



1 Level 3 Data for computers

2 Level 4 Data for computers

3 Reports
for cancer biologists!



- 1. TCGA Analysis Working Groups
- 2. Cancer Biology Community



Reports: Goal

Make effective interpretation of analysis results as efficient as possible.



Reports: Challenges

Number of analyses

~25 modules × ~20 tumor types ≈ 500

2 Amount and depth of results

Spectrum of consumers




Reports: Solution

- Common report structure and layout
 1. Overview, 2. Results, 3. Methods & Data
- Hierarchical organization of content
 Overview first, details on demand
- **3** Highlighting of significant findings

Implementation in Nozzle R package
See my poster for details



Reports: Demo






Reports: Issues

microRNA and mutation data


TumorType	Biospecimen	Any_Level_1	Clinical	CNA	Methylation	mRNA	miR	MAF
BLCA	26	12	9	9	0	0	0	0
BRCA	647	390	353	375	186	434	0	0
CESC	23	8	5	8	0	0	0	0
COAD	245	151	207	182	167	155	0	88
COADREAD	338	203	285	253	236	224	0	139
GBM	508	476	465	466	288	506	415	199
HNSC	59	59	0	57	0	0	0	0
KIRC	460	347	192	345	219	72	0	0
KIRP	75	16	17	16	36	41	0	0
LAML	202	0	0	0	188	0	178	135
LGG	30	0	19	0	0	0	0	0
LIHC	38	0	0	0	0	0	0	0
LUAD	158	21	47	56	128	33	0	0
LUSC	184	161	72	142	133	134	0	0
OV	592	570	528	519	425	570	566	383
PRAD	65	0	0	0	0	0	0	0
READ	93	52	78	71	69	69	0	51
STAD	111	35	0	81	82	0	0	0
THCA	39	25	0	24	0	0	0	0
UCEC	298	24	127	133	70	0	0	0
Totals	3853	2347	2119	2484	1991	2014	1159	856



Reports: Issues



50% of all analysis modules affected





Broad GDAC Analysis Summary 2011_04_21 Run

Tables of Ingested Data: HTML PNG TSV

Tumor Type	# Completed	Percentage		
ov	24	<u>100%</u>		
GBM	24	<u>100%</u>		
COAD	14	<u>58%</u>		
READ	13	<u>54%</u>		
FULL	13	<u>54%</u>		
COADREAD	13	<u>54%</u>		
LUSC	12	<u>50%</u>		
LUAD	12	<u>50%</u>		
BRCA	12	<u>50%</u>		
KIRC	10	<u>42%</u>		
KIRP	9	<u>38%</u>		
UCEC	4	<u>17%</u>		
CESC	4	<u>17%</u>		
BLCA	4	<u>17%</u>		
STAD	3	<u>13%</u>		
HNSC	3	<u>13%</u>		
THCA	2	<u>8%</u>		
LAML	2	<u>8%</u>		
LGG	1	<u>4%</u>		
PRAD	0	<u>0%</u>		
LIHC	0	<u>0%</u>		

This File Generated on: Wed Apr 27 14:57:41 EDT 2011

relate_Clinical_vs_Molecular_Signatures

50% of all analysis modules affected



Reports: Questions

When should we share these reports?

With whom should we share these reports?

How do we address patient privacy issues?